Brazil's Chagas Disease Burden Revealed: Screening Gaps and Treatment Failures in Endemic Rural Areas

In two rural municipalities in Bahia, Brazil, researchers looked back at five years of medical records and found a disease that was hiding in plain sight. Chagas disease, a parasitic infection that can silently damage the heart and digestive system over decades, was being detected in Tremedal but barely screened for at all in Novo Horizonte—despite both towns sitting in the same endemic zone where the infection has long persisted. The difference had nothing to do with who was actually sick. It had everything to do with who was being tested.

Between 2019 and 2023, before a new public health initiative called the Oxente Chagas Bahia Project began its work, the two municipalities told starkly different stories. In Tremedal, serological testing expanded substantially, driven largely by three family physicians who took it upon themselves to screen for the disease. In Novo Horizonte, testing remained minimal—handled by a single health worker at one urban clinic—despite national guidelines and a state health directive explicitly recommending routine screening in endemic areas, including during prenatal visits. When researchers analyzed the data, they found thirteen confirmed cases across both municipalities. The clinical picture was grim: most patients were already in the chronic phase of infection, many showing the cardiac and digestive damage that comes from years of untreated disease. Only two of the thirteen had received antiparasitic treatment, despite being eligible under Brazilian clinical guidelines.

The disease itself moves slowly and often invisibly. Trypanosoma cruzi, the parasite that causes Chagas, is transmitted primarily through the feces of infected triatomine insects—commonly called kissing bugs—though congenital transmission from mother to child remains a significant route. In the acute phase, infection is often asymptomatic. But in untreated individuals, the parasite settles into a chronic phase that can last decades, progressively damaging heart tissue and the nerve cells that control the esophagus and colon. About one-third of chronically infected people develop clinically significant disease: Chagas cardiomyopathy, characterized by conduction abnormalities and heart failure, or severe digestive involvement like megaesophagus or megacolon—conditions where the organ swells and loses the ability to move food or waste through the body.

In the thirteen cases identified, the burden was substantial. Nine patients showed the indeterminate form—infection confirmed but no overt organ damage yet documented. But four had already progressed to symptomatic disease. Three presented with digestive involvement, a proportion higher than the typical 10 to 15 percent seen in other endemic cohorts. One patient underwent Duhamel surgery for megacolon. Two others had advanced esophageal disease, including one with a history of surgical intervention and persistent difficulty swallowing. These conditions carry profound consequences in rural, low-income communities. Progressive dysphagia and chronic constipation impair nutrition and restrict physical capacity, often making it impossible for patients to perform the work that sustains their families. The researchers also identified a pediatric case—a child aged 10 to 19 years—raising urgent questions about whether transmission was still occurring through residual vector activity or congenital infection.

The treatment gap was striking. Brazilian clinical guidelines recommend antiparasitic therapy with benznidazole for eligible patients, particularly younger individuals who are more likely to benefit and less likely to experience adverse effects. Yet only two of the thirteen confirmed cases had documented benznidazole use. Both were older than fifty, an age group for which the guidelines explicitly state that routine etiological treatment is not recommended due to greater uncertainty of benefit. One had established cardiac involvement, a condition for which the landmark BENEFIT trial showed that benznidazole did not significantly reduce clinical deterioration. Meanwhile, several younger patients—including the pediatric case—received no documented treatment. The child's family relocated from the municipality before treatment could be initiated, precluding any follow-up care.

The disparities between the two municipalities reflected deeper structural problems in how rural health systems operate. Testing turnaround times differed: fourteen days in Tremedal versus ten days in Novo Horizonte, a variation driven by differences in laboratory processing capacity and testing frequency. Samples from Novo Horizonte traveled to the central state laboratory in Salvador, while Tremedal's samples went to a regional branch that processed lower volumes and did not perform daily analyses. Prolonged turnaround times, the researchers noted, may discourage clinicians from ordering tests in the first place, delay confirmatory diagnosis, and make it harder to contact patients after results arrive—a particular challenge in rural settings with limited follow-up infrastructure. The concentration of screening in Tremedal among three engaged family physicians suggested that detection was driven by individual clinical awareness and local leadership rather than systematic, guideline-directed practice. In Novo Horizonte, the absence of confirmed cases almost certainly reflected limited testing rather than true absence of disease.

The study also revealed the limits of what routine medical records could capture. Diagnostic procedures and specialist evaluations performed outside the municipalities often went undocumented in local electronic health systems. Echocardiographic data were missing for three of the thirteen patients, making it impossible to fully assess subclinical cardiac involvement. One patient, aged 70 to 79, died, but the cause could not be determined—a gap that illustrated broader deficiencies in rural diagnostic capacity and the integration of clinical information. These limitations, the researchers emphasized, were not merely methodological constraints; they reflected real structural inadequacies in how rural health networks function. The study establishes a baseline picture of Chagas disease burden and healthcare gaps in these two municipalities before the Oxente Chagas Bahia Project begins its work to strengthen surveillance, validate rapid diagnostic tests, and expand access to clinical evaluation and treatment within Brazil's public health system.